(redirected from Oxytrol)
Also found in: Dictionary.


an anticholinergic and antimuscarinic having direct antispasmodic effects on smooth muscle; used orally as the chloride salt in treatment of uninhibited neurogenic bladder and reflex neurogenic bladder.


Cystrin (UK), Kentera (UK), Oxytrol

Pharmacologic class: Anticholinergic

Therapeutic class: Urinary tract antispasmodic

Pregnancy risk category B


Inhibits acetylcholine action at postganglionic receptors, relaxing smooth muscle lining of GU tract and preventing bladder irritability


Syrup: 5 mg/5 ml

Tablets: 5 mg

Tablets (extended-release): 5 mg, 10 mg, 15 mg

Topical gel: 1 g in 1.14-ml sachet

Transdermal system (patch): 39 cm2/36 mg

Indications and dosages

Frequent urination, urinary urgency or incontinence, and nocturia caused by neurogenic bladder; overactive bladder

Adults: 5 mg P.O. two to three times daily (not to exceed 5 mg q.i.d.); or 5 to 15 mg P.O. once daily (extended-release); or one 3.9 mg/day transdermal system applied twice weekly; or apply contents of one gel sachet daily.

Children older than age 5: 5 mg P.O. b.i.d., to a maximum of 5 mg t.i.d.

Dosage adjustment

• Elderly patients


• Hypersensitivity to drug
• Glaucoma
• Intestinal obstruction, severe colitis, atony, paralytic ileus, megacolon, or hemorrhage
• Obstructive uropathy, urinary retention
• Myasthenia gravis
• Acute hemorrhage with shock


Use cautiously in:
• cardiovascular disease, hyperthyroidism, GI disease
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 5 (safety not established).


• Give oral forms without regard to food.
• Don't crush or break tablets.
• Apply contents of one gel sachet to dry, intact skin on the abdomen, upper arms, shoulders, or thighs.

Adverse reactions

CNS: dizziness, drowsiness, hallucinations, insomnia, weakness, anxiety, restlessness, headache

CV: palpitations, hypotension, tachycardia

EENT: blurred vision, cycloplegia, increased intraocular pressure, mydriasis, photophobia

GI: nausea, vomiting, diarrhea, constipation, bloating, dry mouth

GU: urinary hesitancy, urinary retention, erectile dysfunction, suppressed lactation

Metabolic: hyperthermia

Skin: decreased sweating, urticaria, application-site reactions

Other: allergic reactions, fever, hot flashes


Drug-drug.Anticholinergics, anticholinergic-like drugs (including amantadine, antidepressants, disopyramide, haloperidol, phenothiazines): additive anticholinergic effects

Atenolol: increased atenolol absorption

CNS depressants (including antidepressants, antihistamines, opioids, sedative-hypnotics): additive CNS depression

Digoxin: increased digoxin blood level (with extended-release oxybutynin)

Haloperidol: decreased haloperidol blood level, tardive dyskinesia, worsening of schizophrenia

Levodopa: decreased levodopa efficacy

Nitrofurantoin: increased nitrofurantoin blood level, greater risk of toxicity

Drug-herbs.Angel's trumpet, jimsonweed, scopolia: increased anticholinergic effects

Drug-behaviors.Alcohol use: additive CNS depression

Patient monitoring

• Monitor vital signs and temperature. Watch for hypotension, fever, and tachycardia.
• Evaluate patient's vision.
• Assess results of cystometric studies. Stay alert for urinary retention.

Patient teaching

• Tell patient he may take with or without food. Caution him not to crush, break, or chew extended-release tablets.
• Instruct patient to apply transdermal patch to dry, intact skin on abdomen, hip, or buttock. Tell him to use a new skin area with each new system and not to reapply new patch to same site within 7 days. Caution him not to cut or puncture patch.
• Instruct patient to apply contents of one gel sachet daily to dry, intact skin on the abdomen, upper arms, shoulders, or thighs. Tell patient to use a new skin area daily. Advise patient to cover application site with clothing if skin-to-skin contact at application site is anticipated and to wash hands immediately after product application. Warn patient that gel is flammable and to avoid open fire or smoking until gel has dried.
• Tell patient to report blurred vision, fever, skin rash, nausea, or vomiting.
• Advise patient he'll need to undergo periodic bladder exams.
• Caution patient to avoid driving and other hazardous activities if drug causes drowsiness or blurred vision.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, herbs, and behaviors mentioned above.


/oxy·bu·ty·nin/ (-bu´tĭ-nin) an anticholinergic having direct antispasmodic effect on smooth muscle; used as the chloride salt in the treatment of uninhibited or reflex neurogenic bladder.


An anticholinergic drug, C22H31NO3, used to treat incontinence and other urinary symptoms.


Ditropan® Urology A spasmolytic anticholinergic GI and GU tract colic used to ↓ urge incontinence, overactive bladder, bladder Sx associated with neurogenic bladder–eg, frequency, urgency, dysuria, urinary leakage Contraindications Urinary retention, gastric retention, narrow-angle glaucoma Adverse effects Dry mouth, constipation, somnolence, diarrhea, blurred vision, dry eyes, dizziness, rhinitis. See Urge incontinence.


An anticholinergic antispasmodic drug used to treat urinary urgency, frequency and incontinence and bed-wetting in children. Brand names are Cystrin, Ditropan and Lyrinel XL.


an anticholinergic having direct antispasmodic effect on smooth muscle; used in the treatment of uninhibited neurogenic bladder and reflex neurogenic bladder.
References in periodicals archive ?
htm) FDA announced its approval of Oxytrol , the first OTC to treat frequent urination on January 25.
Food and Drug Administration (FDA) approved OXYTROL FOR WOMEN (oxybutynin transdermal system), the first and only over-the-counter treatment for overactive bladder in women.
based Merck's Oxytrol for Women transdermal patch for the treatment of overactive bladder, which switched in 2013, has been discontinued.
Food and Drug Administration approved Oxytrol for Women.
M2 PHARMA-January 28, 2013-Merck gets US FDA's approval for OTC OXYTROL FOR WOMEN for overactive bladder in women(C)2013 M2 COMMUNICATIONS
Oxybutynin may also be delivered through the skin, with the Oxytrol patch or a gel (Gelnique).
Approved treatments include the oxybutynin transdermal patch Oxytrol and a generic formulation of oxybutynin, said Dr.
WASHINGTON -- Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville today issued the following statement regarding the Food and Drug Administration's approval of Merck's application to switch the overactive bladder treatment Oxytrol for Women([R]) to nonprescription sale:
Nasacort, OXYTROL and VetIQ each hit it big, offering consumers more readily accessible solutions to common human and pet health needs.
We are seeing positive signals from the Food and Drug Administration that the environment is increasingly supportive of switch, as the agency approved two first-in-class switches in 2013: Oxytrol for Women for overactive bladders and Nasocort AQ for allergies.
Homologue par la FDA en 2003, le timbre cutane (Kentera, Oxytrol 3,9 mg, Watson)[sup.